Doxorubicin-Induced Cardiomyopathy
Doxorubicin (Adriamycin) has been employed in medical specialty observe since the late Nineteen Sixties. It control promise as a strong drug within the fight against cancer. The tumors most typically responding to antibiotic drug once it’s given as one agent or together with different antitumour agents embody breast and muscular structure carcinomas; sarcoma, Kaposi’s sarcoma, and soft-tissue sarcomas; and Hodgkin’s and non-Hodgkin’s lymphomas. different cancers that square measure less awake to antibiotic drug however that square measure still treated with the drug due to its overall advantages embody stomachic, liver, bile-duct, pancreatic, and mucosa carcinomas. However, reports of fatal cardiotoxic effects of antibiotic drug have. [1]
Doxorubicin Cardiomyopathy
Established antibiotic drug unwellness|heart condition|cardiopathy} could be a fatal disease. once symptom heart condition develops, mortality is roughly five hundredth. intensive analysis has been done to grasp the mechanism and pathophysiology of antibiotic drug cardiopathy, and considerable data and skill has been gained. sadly, no effective treatment for established antibiotic drug cardiopathy is presently accessible. intensive analysis has been done and is being done to find preventive treatments. but an efficient and clinically applicable preventive treatment is nonetheless to be discovered. [2]
Pharmacokinetics of Pegylated Liposomal Doxorubicin
Pegylated liposomal antibiotic drug (doxorubicin HCl cyst injection; Doxil® or Caelyx®) may be a liposomal formulation of antibiotic drug, reducing uptake by the reticulo-endothelial system thanks to the attachment of polythene glycol polymers to a macromolecule Associate in Nursingchor and stably holding drug as a results of liposomal denial via an ammonium ion sulphate chemical gradient. These options end in a pharmacokinetic profile defined by Associate in Nursing extended circulation time and a reduced volume of distribution, thereby promoting growth uptake. [3]
miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells
Doxorubicin is conventionally employed in therapy against carcinoma (HCC), however noninheritable resistance developed throughout long medical care limits its edges. Autophagy, a preserved catabolic method for cellular self-defense and adaptation to the ever-changing atmosphere, is thought to be a possible clinical target to beat antibiotic resistance. during this study, the potential role of miR-223 in modulating doxorubicin-induced autophagy and sensitivity were evaluated in four transfected human HCC cell lines, and also the in vivo connexion was assessed employing a mouse transplant model of HCC. we have a tendency to found that the well-defined miR-223 is expressed at low levels in antibiotic treated HCC cells which miR-223 overexpression inhibits the doxorubicin-induced autophagy that contributes to chemoresistance. [4]
Effective pH-responsive Hydrazine-Modified Silica for Doxorubicin Delivery
Aims: a kind of pH-responsive porous nanosilica (PNS) for antibiotic drug (DOX) delivery exploitation reductant was developed
Study Design: PNS was initial ready by a sol-gel technique so changed with reductant via 3-glycidoxypropyltrimethoxysilane (GPTMS) as coupling agents, (PNS-GPTMS-Hydrazine) for loading of DOX (DOX/PNS-GPTMS-Hydrazine).
Place and period of Study: Department of Biomaterials , Institute of Applied Materials Science, Vietnam Academy of Science and Technology, between February and Gregorian calendar month 2016.
Methodology: The obtained PNS-GPTMS-Hydrazine were characterised by Fourier rework infrared spectrometry (FTIR), thermohydrometric analysis (TGA), and transmission microscopy (TEM). Moreover, DOX loading and unleash behavior of PNS-GPTMS-Hydrazine were additionally evaluated. [5]
Reference
[1] Singal, P.K. and Iliskovic, N., 1998. Doxorubicin-induced cardiomyopathy. New england journal of medicine, 339(13), (Web Link)
[2] Chatterjee, K., Zhang, J., Honbo, N. and Karliner, J.S., 2010. Doxorubicin cardiomyopathy. Cardiology, 115(2), (Web Link)
[3] Gabizon, A., Shmeeda, H. and Barenholz, Y., 2003. Pharmacokinetics of pegylated liposomal doxorubicin. Clinical pharmacokinetics, 42(5), (Web Link)
[4] miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells
Yue Zhou, Enjiang Chen, Yuexiao Tang, Jiayan Mao, Jian Shen, Xiaoxiao Zheng, Shangzhi Xie, Shufen Zhang, Ying Wu, Hao Liu, Xiao Zhi, Tao Ma, Haibin Ni, Jiabin Chen, Kequn Chai & Wei Chen
Cell Death & Disease volume 10, (Web Link)
[5] Vy Vo, U., Vi Tran, T., Minh Thien Nguyen, D., Khoa Nguyen, C., Tram Nguyen Thi, N. and Hai Nguyen, D. (2017) “Effective pH-responsive Hydrazine-Modified Silica for Doxorubicin Delivery”, Asian Journal of Medicine and Health, 4(1), (Web Link)